Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

Q1 Revenue Grew, Beat Consensus

 
• By Mandy Jackson
  
With its next big Phase III readouts in 2026 and beyond, Leqembi remains the biggest focus for Biogen investors (Shutterstock)

More from Earnings

More from Supply Chain